Figure 6

The anti-tumor effect of Apo2L/TRAIL and gemcitabine in combination is greater than that of either single agent alone. Mice were engrafted with two different patient tumors: A-D, Tumor #2; E-H, Tumor #5. Treatment: A, E. Control; B, F. Apo2L/TRAIL; C, G. gemcitabine; D, H. combination therapy. Although tumors showed variable degrees of sensitivity to either Apo2L/TRAIL or gemcitabine alone, the combination treatment resulted in significant inhibition of tumor growth (D, p = 0.035; H, p = 0.05).